Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The series B round comes shortly after Actuate dosed the first patient in a phase 1/2 trial of glycogen synthase kinase‐3 beta 9-ING-41.
AZ nets exec to lead breast cancer R&D; Teva stars in price-fix plot, but attorneys general say others "willingly" joined; EUSA Pharma nabs new…
Roche subsidiary Genentech put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune diseases.
Immune molecules from sea lampreys could inspire new treatments for brain tumors, trauma and neurodegenerative diseases.
In this week's EuroBiotech Report, Bayer pumps $150 million into cell therapies, Merck KGaA retools F-star pact and Philogen raises $70 million.
In our EuroBiotech roundup this week, uniQure posts gene therapy data, Modus’ sickle cell trial fails and TreeFrog raises cash for cell therapy R&D.
The deal effectively sees Essa trade its shares for Realm’s cash, giving it the financial means to advance its pipeline of cancer drugs.
The data show early signs of efficacy, with one-third of the heavily pretreated lung cancer patients enrolled in the trial having partial responses.…
The R&D shake-up at AstraZeneca continues as it hires cancer researcher Dr. Sunil Verma to run its breast cancer work.
Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.
